5 Best Growth Stocks Under $20 to Buy

2. Erasca Inc. (NASDAQ:ERAS)

Number of Hedge Fund Holders: 51

Erasca Inc. (NASDAQ:ERAS) is one of the best growth stocks under $20 to buy. On May 11, Erasca reported positive progress for its precision oncology pipeline, highlighting monotherapy efficacy and a favorable safety profile for its lead candidate, ERAS-0015, in KRAS G12X lung and pancreatic cancers. The company is accelerating development, having already initiated monotherapy expansion and combination dose escalation cohorts ahead of schedule.

Data from these programs are expected in H1 2027, with ERAS-0015 also positioned as a potential backbone for combination therapies following new clinical collaborations with Merck and Tango Therapeutics. The company is also advancing its pan-KRAS inhibitor, ERAS-4001, which recently received a US composition of matter patent extending protection until 2043.

Preliminary safety, pharmacokinetic, and early efficacy data for ERAS-4001 are anticipated in H2 2026. These clinical advancements are supported by a strengthened global strategy, including the consolidation of worldwide rights for ERAS-0015. Financially, Erasca Inc. (NASDAQ:ERAS) remains well-positioned with $409 million in cash and marketable securities as of March 31, supported by a $258.8 million public offering completed in January. This capital position is expected to fund operations into H2 2028.

Erasca Inc. (NASDAQ:ERAS) is a California-based clinical-stage precision oncology company that provides solutions for patients with RAS/MAPK pathway-driven cancers. The company’s core therapies include ERAS-0015, ERAS-4001, and ERAS-12.